Zobrazeno 1 - 10 of 19 836 pro vyhledávání: '"Anti-Epidermal Growth Factor Receptor"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
In silico designing and optimization of anti‐epidermal growth factor receptor scaffolds by complementary‐determining regions‐grafting technique.
Autor: Rezaei Adriani, Razieh1, Mousavi Gargari, Seyed Latif1 slmousavi@shahed.ac.ir, Bakherad, Hamid2 Bakheradh@pharm.mui.ac.ir, Amani, Jafar3
Publikováno v: Quantitative Biology. Sep2024, Vol. 12 Issue 3, p301-312. 12p.
Zobrazit plný text záznamu
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Akademický článek
Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with chemoradiotherapy for induction chemotherapy resistant locally advanced nasopharyngeal carcinoma: A prospective phase II study
Autor: Xiaoshuang Niu, Peiyao Liu, Xin Zhou, Dan Ou, Xiaoshen Wang, Chaosu Hu
Publikováno v: Translational Oncology, Vol 39, Iss , Pp 101797- (2024)
Objectives: To investigate the efficacy and safety of nimotuzumab (NTZ) combined with concurrent chemo-radiotherapy (CCRT) in induction chemotherapy (IC) resistant locally advanced nasopharyngeal carcinoma (LANPC). Materials and methods: A single-arm
Externí odkaz: https://doaj.org/article/575384c736934dd5af224470e51c3ef9
Zobrazit plný text záznamu
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Akademický článek
Precision Cancer Therapy Enabled Anti-Epidermal Growth Factor Receptor-Conjugated Manganese Core Phthalocyanine Bismuth Nanocomposite for Dual Imaging-Guided Breast Cancer Treatment.
Autor: Mondal S; Digital Healthcare Research Center, Pukyong National University., Park S; Industry 4.0 Convergence Bionics Engineering, Department of Biomedical Engineering, Pukyong National University, Busan 48513, Republic of Korea., Nguyen VT; Industry 4.0 Convergence Bionics Engineering, Department of Biomedical Engineering, Pukyong National University, Busan 48513, Republic of Korea., Doan VHM; Industry 4.0 Convergence Bionics Engineering, Department of Biomedical Engineering, Pukyong National University, Busan 48513, Republic of Korea., Choi J; Smart Gym-Based Translational Research Center for Active Senior's Healthcare, Pukyong National University, Busan 48513, Republic of Korea., Ly CD; Industry 4.0 Convergence Bionics Engineering, Department of Biomedical Engineering, Pukyong National University, Busan 48513, Republic of Korea., Phan DT; Industry 4.0 Convergence Bionics Engineering, Department of Biomedical Engineering, Pukyong National University, Busan 48513, Republic of Korea., Truong TT; Industry 4.0 Convergence Bionics Engineering, Department of Biomedical Engineering, Pukyong National University, Busan 48513, Republic of Korea., Vo TH; Industry 4.0 Convergence Bionics Engineering, Department of Biomedical Engineering, Pukyong National University, Busan 48513, Republic of Korea., Nguyen DT; Industry 4.0 Convergence Bionics Engineering, Department of Biomedical Engineering, Pukyong National University, Busan 48513, Republic of Korea., Pal U; Institute of Physics, Autonomous University of Puebla, Puebla, Pue. 72570, Mexico., Lee B; Digital Healthcare Research Center, Pukyong National University.; Industry 4.0 Convergence Bionics Engineering, Department of Biomedical Engineering, Pukyong National University, Busan 48513, Republic of Korea.; Smart Gym-Based Translational Research Center for Active Senior's Healthcare, Pukyong National University, Busan 48513, Republic of Korea.; Department of Smart Healthcare, Pukyong National University, Busan 48513, Republic of Korea., Oh J; Digital Healthcare Research Center, Pukyong National University.; Industry 4.0 Convergence Bionics Engineering, Department of Biomedical Engineering, Pukyong National University, Busan 48513, Republic of Korea.; Smart Gym-Based Translational Research Center for Active Senior's Healthcare, Pukyong National University, Busan 48513, Republic of Korea.; Department of Smart Healthcare, Pukyong National University, Busan 48513, Republic of Korea.; Ohlabs Corp., Busan 48513, Republic of Korea.
Publikováno v: Biomaterials research [Biomater Res] 2024 Nov 07; Vol. 2024, pp. 0092. Date of Electronic Publication: 2024 Nov 07 (Print Publication: 2024).
Zobrazit plný text záznamu
10
Editorial & Opinion
How to Test HER2 for Predicting Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer? Evidence From the Secondary Analysis of Biomarkers of CALGB/SWOG 80405.
Autor: Sartore-Bianchi A; Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, 'Mario Negri' Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Università degli Studi di Torino, Turin, Italy, Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy., Marsoni S; Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, 'Mario Negri' Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Università degli Studi di Torino, Turin, Italy, Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy., Amatu A; Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, 'Mario Negri' Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Università degli Studi di Torino, Turin, Italy, Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy., Torri V; Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, 'Mario Negri' Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Università degli Studi di Torino, Turin, Italy, Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy., Bonoldi E; Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, 'Mario Negri' Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Università degli Studi di Torino, Turin, Italy, Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy., Bardelli A; Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, 'Mario Negri' Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Università degli Studi di Torino, Turin, Italy, Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy., Trusolino L; Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, 'Mario Negri' Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Università degli Studi di Torino, Turin, Italy, Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy., Siena S; Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, 'Mario Negri' Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Università degli Studi di Torino, Turin, Italy, Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Oct 20; Vol. 42 (30), pp. 3631-3632. Date of Electronic Publication: 2024 Jul 30.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje